Goldman Sachs, Morgan Stanley Bullish on BioAge, Cite Lilly Relationship
Novo Nordisk Semaglutide Cut Cardio Risks by 14% in Diabetics: Study
Report: novo-nordisk a/s weight loss drug Ozempic's 'sister drug' significantly reduces heart disease risk in experiments.
Patients with type 2 diabetes and a history of heart disease, chronic kidney disease, etc., have a 14% lower probability of experiencing cardiovascular events after taking Rybelsus compared to patients taking a placebo.
Studies show that novo-nordisk a/s (NVO.US) oral semaglutide reduces the risk of heart disease.
Rybelsus, an oral semaglutide under novo-nordisk a/s, reduced the risk of heart attacks and strokes in a large study, potentially leading to wider use of the medication.
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk Says Its Rybelsus Oral Semaglutide Reduces Risk of Major Adverse Cardiovascular Events